Alexey V. Danilov, MD, PhD

Articles

Frontline Treatment Approaches in CLL

November 15th 2021

Drs Alexey Danilov and Anthony Mato review treatment options available for newly diagnosed chronic lymphocytic leukemia and describe decisions for monotherapy vs combination therapy.

Repeat Prognostic Testing in CLL

November 11th 2021

Drs Alexey Danilov and Anthony Mato recommend when hematologists and oncologists should consider repeat molecular testing for patients with chronic lymphocytic leukemia.

Diagnostic Testing for Newly Diagnosed CLL

November 11th 2021

Recommendations for conducting imaging scans and biopsies to help guide the treatment of newly diagnosed chronic lymphocytic leukemia.

Prognostic Testing and Chemoimmunotherapy Use in CLL

November 4th 2021

The types of prognostic assays used to help determine candidacy for chemoimmunotherapy as frontline treatment for chronic lymphocytic leukemia.

Current Approaches to Assessing Patients With CLL

November 4th 2021

Drs Alexey Danilov and Anthony Mato highlight their preferences for diagnostic and prognostic testing when evaluating patients with chronic lymphocytic leukemia.

Dr. Danilov on the Rationale to Target MCL1 and BCLX in CLL

November 1st 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Dr. Danilov on the Safety Profile of Entospletinib Plus Obinutuzumab in CLL

October 21st 2021

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Danilov on the Rationale to Combine Entospletinib With Obinutuzumab in CLL

October 14th 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Danilov on the Efficacy of Entospletinib Plus Obinutuzumab in Relapsed/Refractory CLL

September 19th 2021

Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Danilov on the Need to Identify Novel Pathways in CLL

September 11th 2021

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.

Dr. Danilov on the Utility of BTK Inhibitors in CLL

September 8th 2021

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

Dr. Danilov on the Efficacy of the Combination Zandelisib and Zanubrutinib in R/R B-Cell Malignancies

August 13th 2021

Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

Dr. Danilov on the Role of Disease Biology in Up-front Treatment Selection in CLL

November 10th 2020

Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.

Dr. Danilov on the Role of Chemoimmunotherapy in CLL

October 26th 2020

Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Danilov on Venetoclax Plus BTK Inhibitors in CLL

April 7th 2020

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Dr. Danilov on ELEVATE-TN Trial Results in CLL

February 21st 2020

Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Danilov on Utility of Rituximab Biosimilars in CLL

December 14th 2019

Alexey V. Danilov, MD, PhD, discusses the utility of rituximab biosimilars in chronic lymphocytic leukemia.